[Efalizumab in treating psoriasis]

Department of Science and Technology - Brazilian Health Technology Assessment General Coordination
Record ID 32006001460
Authors' objectives:

To evaluate the effectiveness and safety of Efalizumab (Raptiva™) in the treatment of psoriasis and its diversity of clinical manifestations.

Authors' recommendations: The evidence available indicates the effectiveness and safety of efalizumab, when compared to placebo, in the treatment of patients with the diagnosis of moderate to severe plaque psoriasis, from 12 to 24-week periods, according to clinical and self-reported responses. Because of the incompatibility between the treatment periods tested (12 and 24 weeks) and the chronic characteristics of the disease, the authors consider the adoption of such a strategy premature due to the lack of evidence supported by longer term studies. However, it is recommended that the option for such treatment be secondary to the failure of traditional and more inexpensive strategies, considering the efficiency of each option.
Project Status: Completed
Year Published: 2005
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Brazil
MeSH Terms
  • Antibodies, Monoclonal
  • Psoriasis
Organisation Name: Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
Contact Address: Ministerio da Saude, Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia, Esplanada dos Ministerios, Edificio sede; bl "G" - 8 andar - SL 834, CEP: 70058-900, Brasilia, DF Brazil, Tel: +55 61 3315 3197 Fax: +55 61 3315 3850
Contact Name: suzanne.jacob@saude.gov.br
Contact Email: suzanne.jacob@saude.gov.br
Copyright: Department of Science and Technology - Brazilian Health Technology Assessment General Coordination (DECIT-CGATS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.